What’s Propelling Edwards Lifesciences Corporation (EW) to Reach All-Time High?

March 14, 2018 - By Stephen Andrade

The stock of Edwards Lifesciences Corporation (NYSE:EW) reached all time high today, Mar, 14 and still has $150.55 target or 7.00 % above today’s $140.70 share price. This indicates more upside for the $29.55B company. This technical setup was reported by Barchart.com. If the $150.55 PT is reached, the company will be worth $2.07B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock decreased 0.09% or $0.13 during the last trading session, reaching $140.7. About 670,617 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since March 14, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 EPS, up 17.02 % or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.02M for 31.98 P/E if the $1.10 EPS becomes a reality. After $0.94 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02 % EPS growth.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp had 106 analyst reports since July 30, 2015 according to SRatingsIntel. The stock has “Neutral” rating by SunTrust on Friday, January 8. Cowen & Co initiated Edwards Lifesciences Corporation (NYSE:EW) rating on Friday, October 9. Cowen & Co has “Outperform” rating and $185 target. Northland Capital downgraded Edwards Lifesciences Corporation (NYSE:EW) on Tuesday, April 5 to “Market Perform” rating. The firm has “Overweight” rating given on Monday, April 11 by JP Morgan. The company was maintained on Monday, September 4 by Canaccord Genuity. The firm earned “Buy” rating on Monday, April 4 by BTIG Research. Canaccord Genuity maintained it with “Buy” rating and $174.0 target in Thursday, February 15 report. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Sell” rating by Citigroup on Thursday, November 12. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, May 30. The rating was maintained by Cowen & Co with “Outperform” on Wednesday, April 27.

More news for Edwards Lifesciences Corporation (NYSE:EW) were recently published by: Gurufocus.com, which released: “Edwards Lifesciences Corp (EW) Files 10-K for the Fiscal Year Ended on …” on February 16, 2018. Gurufocus.com‘s article titled: “Giverny Capital Inc. Buys Credit Acceptance Corp, Edwards Lifesciences Corp …” and published on February 13, 2018 is yet another important article.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $29.55 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 52.11 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: